Home Family Medicine Scrotal Pain

Scrotal Pain

📋 Key Information Summary

📋
  • Scrotal pain is a surgical emergency until proven otherwise — testicular torsion must be excluded in all males presenting with acute scrotal pain, particularly those aged 12–25 years.
  • The "window of salvageability" for torsion is approximately 6 hours from symptom onset; beyond 12 hours the risk of testicular loss exceeds 75%. Do not delay surgical exploration for imaging when clinical suspicion is high.
  • Colour Doppler ultrasonography (US) is the first-line imaging modality when the diagnosis is equivocal, with sensitivity and specificity exceeding 90% for testicular torsion in experienced hands.
  • Epididymo-orchitis is the most common cause of acute scrotal pain in sexually active males aged 15–35 years; Chlamydia trachomatis and Neisseria gonorrhoeae are the leading aetiologies in this cohort.
  • Blue dot sign (palpable nodule on superior testis) is pathognomonic for torsion of the testicular appendage (hydatid of Morgagni) — a self-limiting condition managed conservatively.
  • Testicular malignancy accounts for approximately 1% of all male cancers in Australia and is the most common solid tumour in males aged 15–44 years; any painless or painful firm intratesticular mass warrants urgent urological referral and tumour marker assessment (AFP, β-hCG, LDH).
  • Prehn's sign (relief of pain with testicular elevation) may suggest epididymo-orchitis over torsion, but is unreliable and should never be used to exclude torsion.
  • Empirical antibiotics for suspected epididymo-orchitis should cover both C. trachomatis and N. gonorrhoeae in sexually active men: ceftriaxone 500 mg IM stat + doxycycline 100 mg PO BD for 10–14 days.
  • For males >35 years with suspected epididymo-orchitis, consider enteric organisms (E. coli, Proteus); use trimethoprim 300 mg PO daily for 14 days or a fluoroquinolone if resistant pathogens are suspected.
  • All patients undergoing surgical exploration for suspected torsion should receive bilateral orchidopexy — the contralateral testis is at risk of future torsion.
  • Testicular trauma with suspected rupture requires urgent surgical exploration within 6 hours; scrotal US supports diagnosis but should not delay theatre if clinical findings are compelling.
  • Aboriginal and Torres Strait Islander males experience barriers to timely presentation and specialist access; culturally safe education about scrotal symptoms is essential in rural and remote communities.

Introduction & Australian Epidemiology

Scrotal pain is a common presenting complaint in Australian emergency departments and general practice, accounting for an estimated 0.5% of all ED presentations in males. The differential diagnosis spans a wide range of conditions — from benign, self-limiting entities (e.g., torsion of a testicular appendage) to true surgical emergencies (e.g., testicular torsion) and sinister diagnoses (e.g., testicular malignancy). A systematic, evidence-based approach to evaluation is essential to avoid delays in treatment, particularly for time-sensitive conditions where outcomes are directly linked to the speed of diagnosis and intervention.

In Australia, testicular torsion occurs at a rate of approximately 3.8 per 100,000 males per year, with a bimodal peak in the neonatal period and during puberty (ages 12–18 years). The underlying anatomical predisposition — the "bell-clapper" deformity — is bilateral in up to 40% of cases. Epididymo-orchitis is the most frequent diagnosis in sexually active males presenting with acute scrotal pain, with Chlamydia trachomatis being the leading sexually transmitted pathogen identified. Notifications of chlamydia in Australia exceeded 100,000 cases in 2022, with the highest rates in males aged 20–29 years (Australian Government Department of Health, National Notifiable Diseases Surveillance System).

Testicular cancer, while relatively uncommon overall (approximately 800 new cases annually in Australia), is the most common solid malignancy in young men aged 15–44 years. Incidence has been increasing over the past three decades. Prognosis is excellent with early detection, with five-year survival exceeding 98% for localised disease. Australia has one of the highest incidence rates of testicular cancer globally, particularly among non-Indigenous males of European descent.

This guideline provides a structured approach to the diagnosis and management of scrotal pain in Australian clinical practice, encompassing acute presentations, red flag identification, and evidence-based treatment pathways aligned with Australian therapeutic standards and PBS availability.

⚠️
Clinical imperative: Any male presenting with acute scrotal pain should have testicular torsion excluded as the first priority. History and examination must be performed promptly; if there is any clinical suspicion of torsion, immediate surgical consultation should be sought without waiting for imaging.

Scrotal Pain Diagnostic Model & Red Flags

A structured diagnostic approach to scrotal pain begins with a focused history, targeted examination, and risk stratification to identify time-critical diagnoses. The clinician must systematically consider the full differential diagnosis, prioritising conditions that require urgent surgical intervention.

Differential Diagnosis Framework

Urgency Diagnosis Key Features Peak Age
Emergency Testicular torsion Sudden onset, severe pain, nausea/vomiting, absent cremasteric reflex, high-riding testis Neonatal & 12–18 years
Emergency Testicular rupture (trauma) History of blunt trauma, severe pain, swelling, ecchymosis, loss of testicular contour 15–40 years
Urgent Epididymo-orchitis Gradual onset, dysuria, urethral discharge, pyuria, swollen epididymis, positive Prehn's sign (unreliable) 15–35 years (STI) / >35 years (UTI)
Urgent Fournier's gangrene Rapidly progressive, crepitus, sepsis, perineal necrotising fasciitis, diabetes mellitus risk factor 50–70 years
Urgent Testicular neoplasm Painless or painful firm intratesticular mass, testicular enlargement, gynaecomastia (rare) 15–44 years
Non-urgent Torsion of testicular appendage Blue dot sign, gradual onset, localised tenderness at upper pole, no systemic symptoms 7–14 years
Non-urgent Varicocele / hydrocele / inguinal hernia Dragging sensation, "bag of worms" (varicocele), transillumination (hydrocele), reducible swelling (hernia) Variable

Red Flags Requiring Immediate Action

🚨
  • Acute onset severe scrotal pain (seconds to minutes) — consider torsion until proven otherwise
  • Absent cremasteric reflex on the affected side — highly sensitive for torsion (LR > 10)
  • High-riding or transversely oriented testis — suggests bell-clapper deformity with torsion
  • Nausea and vomiting with scrotal pain — present in up to 70% of torsion cases
  • Scrotal skin changes (erythema, oedema, ecchymosis) after trauma — consider testicular rupture
  • Systemic signs of sepsis (fever, tachycardia, hypotension) with scrotal pain — consider Fournier's gangrene or complicated epididymo-orchitis
  • Firm, non-tender intratesticular mass — testicular malignancy until excluded by US and tumour markers

Focused History & Examination Approach

1
Onset & Duration
Sudden (seconds–minutes) → torsion likely. Gradual (hours–days) → infection or inflammation more likely. Intermittent episodes → torsion-detorsion.
2
Associated Symptoms
Dysuria, urethral discharge, fever → epididymo-orchitis. Nausea/vomiting → torsion. Abdominal pain → referred pain or torsion.
3
Sexual History
Recent new partner, unprotected intercourse → STI-related epididymo-orchitis. Age >35 with lower urinary tract symptoms → urinary tract infection-related epididymitis.
4
Examination Priorities
Cremasteric reflex (absent = torsion), testicular lie (high-riding = torsion), blue dot sign (appendage torsion), swelling pattern (diffuse vs. focal), Prehn's sign (unreliable alone).

Testicular Torsion vs Epididymo-Orchitis Comparison

Differentiating testicular torsion from epididymo-orchitis is the most critical clinical decision in the evaluation of acute scrotal pain. While clinical features overlap significantly, certain features carry greater discriminatory value. The clinician must maintain a low threshold for surgical exploration when the diagnosis remains uncertain.

Feature Testicular Torsion Epididymo-Orchitis
Onset Sudden (seconds to minutes) Gradual (hours to days)
Pain severity Severe, often excruciating Moderate, worsening progressively
Nausea / vomiting Common (up to 70%) Uncommon
Fever Usually absent early Present in 30–50%
Cremasteric reflex Absent (sensitivity ~100%) Usually present
Testicular lie High-riding, transverse Normal
Epididymis May be tender, anteriorly positioned Swollen, tender, indurated
Prehn's sign Pain worsens with elevation Pain may improve with elevation (unreliable)
Urethral discharge Absent Present in STI-related cases
Urinalysis Usually normal Pyuria, bacteriuria (especially in older men)
Doppler US findings Absent or markedly reduced blood flow, heterogeneous echotexture Increased blood flow to epididymis, reactive hydrocele
Peak age 12–18 years (neonates also) 15–35 years (STI); >35 years (UTI)
Management Immediate surgical exploration + bilateral orchidopexy Antibiotics + scrotal elevation + analgesia
🚨
Never exclude torsion on clinical grounds alone. Studies demonstrate that up to 30% of surgically confirmed torsion cases have atypical features (gradual onset, preserved cremasteric reflex, absence of nausea). If clinical suspicion exists, proceed to urgent surgical exploration or immediate Doppler US — do not adopt a "wait and see" approach.

Testicular Torsion — Detailed Management

Pathophysiology: Testicular torsion involves rotation of the testis on its spermatic cord, resulting in venous congestion followed by arterial occlusion and ischaemia. The underlying predisposition is the "bell-clapper" deformity — an abnormally high attachment of the tunica vaginalis to the spermatic cord, allowing intravaginal rotation. This anomaly is bilateral in 40% of cases.

Salvage rates by time to detorsion:

  • <6 hours: ~90–100% salvage rate
  • 6–12 hours: ~50–70% salvage rate
  • 12–24 hours: ~20% salvage rate
  • >24 hours: Testicular salvage is rare; orchidectomy usually required

Manual detorsion may be attempted as a temporising measure while awaiting theatre. The classical teaching is to "open the book" — externally rotate the testis (medial to lateral, i.e., from the patient's midline outward). This is successful in approximately 30–70% of cases but does not replace surgical exploration and fixation.

Surgical management: Bilateral orchidopexy using non-absorbable suture is the definitive treatment. The affected testis is explored; if viable, orchidopexy is performed. If non-viable (black, non-bleeding), orchidectomy is performed. The contralateral testis is always fixed prophylactically.

Epididymo-Orchitis — Detailed Management

Aetiology by age group:

  • Sexually active males (<35 years): Chlamydia trachomatis (most common), Neisseria gonorrhoeae
  • Males >35 years or men who have sex with men (MSM): Enteric organisms — Escherichia coli, Proteus mirabilis, Klebsiella spp. — associated with urinary tract obstruction, instrumentation, or recent catheterisation
  • Children (pre-pubertal): Usually secondary to UTI; consider anatomical abnormality

Antibiotic Therapy for Epididymo-Orchitis

💊
Ceftriaxone
Rocephin® · Cephalosporin (3rd generation)
Indication STI-related epididymo-orchitis (gonococcal cover)
Adult dose 500 mg IM stat (single dose) — 1 g IM if body weight ≥100 kg
Renal adjustment No adjustment required
PBS status ✔ PBS General Benefit
💊
Doxycycline
Doryx® · Vibramycin® · Tetracycline
Indication STI-related epididymo-orchitis (chlamydial cover)
Adult dose 100 mg PO BD for 10–14 days
Paediatric dose ≥8 years: 2 mg/kg BD (max 100 mg BD)
Renal adjustment No adjustment required; avoid in severe renal impairment (risk of hepatotoxicity)
PBS status ✔ PBS General Benefit
💊
Trimethoprim
Alprim® · Trimethoprim
Indication UTI-related epididymo-orchitis (males >35 years)
Adult dose 300 mg PO daily for 14 days
Renal adjustment eGFR <30 mL/min: avoid or use with caution; consult infectious diseases
PBS status ✔ PBS General Benefit
💊
Ciprofloxacin
Ciproxin® · Fluoroquinolone
Indication Enteric organism epididymo-orchitis (alternative to trimethoprim)
Adult dose 500 mg PO BD for 14 days
Renal adjustment eGFR <30 mL/min: 500 mg PO daily
PBS status ✔ PBS General Benefit
⚠️
Fluoroquinolone resistance: Australian surveillance data show increasing N. gonorrhoeae resistance to ciprofloxacin (~30% of isolates). Ciprofloxacin should NOT be used as monotherapy for suspected gonococcal epididymo-orchitis. Ceftriaxone remains essential for gonococcal cover.

Supportive measures for epididymo-orchitis: scrotal elevation (scrotal support or underwear), ice packs in the first 24–48 hours, NSAIDs (ibuprofen 400 mg PO TDS or naproxen 250–500 mg PO BD) for analgesia and anti-inflammatory effect, and avoidance of sexual contact until the course of antibiotics is completed and symptoms have resolved. Partner notification and treatment are mandatory for STI-related cases.

Torsion of Testicular Appendage

Torsion of a testicular appendage (hydatid of Morgagni) is the most common cause of acute scrotal pain in boys aged 7–14 years. The testicular appendage is a vestigial remnant of the Müllerian (paramesonephric) duct located at the superior pole of the testis. When it undergoes torsion, the resulting ischaemia produces localised pain and inflammation.

Clinical Features

  • Blue dot sign: A tender, blue-black nodule visible or palpable at the upper pole of the testis through the scrotal skin — this is pathognomonic and present in approximately 20–40% of cases (more easily seen in lighter-skinned individuals)
  • Onset: More gradual than testicular torsion (hours rather than seconds), though may still present acutely
  • Pain: Moderate, well-localised to the superior scrotum; may intensify over 24–48 hours before gradually resolving
  • Cremasteric reflex: Typically preserved (key distinguishing feature from torsion)
  • Systemic symptoms: Absent — no nausea, vomiting, or fever
  • Testicular lie: Normal position

Diagnosis

Diagnosis is primarily clinical when the blue dot sign is present. Colour Doppler US is indicated if the diagnosis is uncertain or to exclude testicular torsion — findings include a small avascular nodule at the superior testis with normal testicular blood flow and possible reactive hydrocele. US should not be delayed if torsion cannot be excluded on clinical grounds.

Management

Conservative
Standard Management
Self-limiting condition resolving over 5–7 days. Supportive care is the mainstay of treatment.
Setting: GP / ED discharge
Symptomatic
Analgesic Therapy
NSAIDs (ibuprofen 5–10 mg/kg PO TDS for children, 400 mg PO TDS for adults) for 5–7 days. Paracetamol as adjunct. Scrotal support. Ice packs intermittently.
Setting: Outpatient
Surgical
Rare Indications
Surgical excision of the infarcted appendage is rarely required. Consider if symptoms persist beyond 7–10 days, if the diagnosis remains uncertain, or if there is significant reactive hydrocele causing discomfort.
Setting: Urology referral
ℹ️
Parent counselling point: Reassure parents that the condition is benign and self-limiting. Advise review if pain worsens, if a new swelling develops, or if symptoms fail to improve within 5–7 days. Advise that the contralateral side can be similarly affected, though recurrence is uncommon.

Testicular Neoplasm & Trauma

Testicular Neoplasm

Testicular cancer is the most common solid organ malignancy in Australian males aged 15–44 years, with approximately 800 new diagnoses annually and an age-standardised incidence of 6.5 per 100,000. The incidence has increased by approximately 40% over the past 30 years in Australia. Five-year survival exceeds 98% for localised disease and remains above 90% even with distant metastases, making early detection critical.

Risk factors:

  • Cryptorchidism (undescended testis) — 3- to 8-fold increased risk even after orchidopexy
  • Personal history of testicular cancer — 5% contralateral risk
  • Family history (first-degree relative) — 6- to 10-fold increased risk
  • Testicular dysgenesis syndrome (infertility, hypospadias, cryptorchidism)
  • HIV infection — increased risk of seminoma
  • Ethnicity — higher incidence in Caucasian males compared to Aboriginal and Torres Strait Islander and Asian males

Clinical presentation: Most commonly presents as a painless, firm, non-tender intratesticular mass. However, approximately 20–30% of cases present with pain (acute or chronic), either due to haemorrhage within the tumour, rapid expansion, or concurrent epididymitis. Any intratesticular mass should be considered malignant until proven otherwise — transillumination to distinguish from hydrocele is useful but does not exclude malignancy.

Classification (WHO 2022):

Type Frequency Tumour Markers Key Characteristics
Germ cell tumours (~95%)
— Seminoma ~45% β-hCG (elevated in ~15%) Peak age 25–45; highly radiosensitive; excellent prognosis
— Non-seminomatous germ cell tumour (NSGCT) ~50% AFP (~70%), β-hCG (~60%), LDH Includes embryonal carcinoma, yolk sac tumour, choriocarcinoma, teratoma; mixed tumours common
Sex cord-stromal tumours (~5%) ~5% Usually normal Leydig cell tumour, Sertoli cell tumour; may secrete androgens/oestrogens

Urgent Investigation Pathway

1
Scrotal Ultrasound
High-resolution colour Doppler US is the first-line investigation. Sensitivity for detecting intratesticular masses exceeds 95%. If a solid intratesticular mass is identified, proceed to tumour markers and urology referral.
2
Tumour Markers
Serum AFP, β-hCG, LDH — drawn BEFORE orchidectomy. AFP has a half-life of 5–7 days, β-hCG 24–36 hours. LDH is a non-specific marker of tumour burden.
3
CT Abdomen/Pelvis
Staging CT of abdomen and pelvis with IV contrast for retroperitoneal lymphadenopathy assessment. Chest CT or X-ray for pulmonary metastases.
4
Radical Inguinal Orchidectomy
Definitive diagnosis and primary treatment via inguinal approach (NOT scrotal/Trans-scrotal biopsy — contraindicated due to risk of tumour seeding). Performed by urologist.
⚠️
Trans-scrotal biopsy or excision is contraindicated. All suspected testicular malignancies must be managed via inguinal approach with control of the spermatic cord prior to mobilisation. Trans-scrotal intervention risks tumour seeding into the scrotal skin and lymphatic channels, altering the staging and prognosis.

Testicular Trauma

Testicular trauma accounts for approximately 1% of all trauma presentations. Blunt trauma (e.g., sports injuries, assault, straddle injuries) is more common than penetrating trauma. The testis is relatively well-protected by the cremasteric muscle, dartos muscle, and tunica albuginea, but significant force can result in contusion, haematocele, or rupture.

Classification of testicular injuries:

Mild
Testicular Contusion
Oedema and ecchymosis without disruption of the tunica albuginea. Testicular architecture preserved on US.
Setting: Outpatient follow-up
Moderate
Haematocele / Tunica Albuginea Injury
Blood collection within the tunica vaginalis. US may show heterogeneity. May require surgical exploration if expanding.
Setting: Urology observation ± surgery
Severe
Testicular Rupture
Disruption of tunica albuginea with extrusion of seminiferous tubules. US shows irregular contour, heterogeneous echotexture. Requires urgent surgical exploration and repair within 6 hours.
Setting: Emergency surgery

Management principles:

  • Initial assessment: Scrotal US with Doppler is the investigation of choice. Assessment of testicular integrity (tunica albuginea disruption) and vascularity.
  • Conservative management (contusion): Scrotal support, ice packs (20 minutes on / 20 minutes off), bed rest, NSAIDs for analgesia, and close outpatient follow-up with repeat US in 1–2 weeks.
  • Surgical exploration (rupture or suspected rupture): Orchidopexy and repair of tunica albuginea if the testis is salvageable (salvage rate ~90% if explored within 72 hours). Orchidectomy if the testis is non-viable.
  • Tetanus prophylaxis: Assess and update tetanus immunisation for penetrating injuries.
  • Haematocele: Large or expanding haematoceles require surgical drainage to prevent infection and secondary testicular atrophy.
⚠️
Athletic cup / protective equipment: Encourage use of protective cups for contact sports (cricket, AFL, rugby, martial arts) to reduce the risk of testicular trauma. This is especially important in adolescents with testicular pain-related sporting injuries being a common presentation to Australian EDs.

Investigations

Investigation selection depends on the clinical scenario, available resources, and time-sensitivity of the suspected diagnosis. The following outlines the recommended investigation approach for scrotal pain presentations.

First-Line Investigations

Essential Scrotal Ultrasound (Colour Doppler) High-resolution (≥12 MHz linear probe) colour Doppler US is the gold-standard imaging modality for scrotal pathology. Sensitivity/specificity for torsion: >90%/~100% (operator-dependent). Availability: major hospitals (24/7), most radiology practices (same-day). MBS item 55062.
Essential Urinalysis (MSU or dipstick) Midstream urine for microscopy, culture, and sensitivity. Positive for pyuria and/or bacteriuria in epididymo-orchitis (especially older males). STI screening: first-void urine for NAAT (C. trachomatis and N. gonorrhoeae). MBS item 69310 (NAAT).
Available STI Screening (NAAT) First-void urine nucleic acid amplification test for C. trachomatis and N. gonorrhoeae. Also consider syphilis serology and HIV testing. Available at sexual health clinics, GP, and hospitals. Results within 1–3 days.
Available Tumour Markers (AFP, β-hCG, LDH) Drawn BEFORE orchidectomy if testicular malignancy suspected. AFP has 5–7 day half-life; β-hCG 24–36 hours. Available at all major laboratories. Essential for staging and monitoring. MBS items 66517 (AFP), 66518 (β-hCG).
Available CT Abdomen/Pelvis with IV Contrast Staging investigation for confirmed testicular malignancy — assesses retroperitoneal lymphadenopathy and visceral metastases. MBS item 56003.

Additional Investigations

Specialist Radionuclide Scintigraphy (Testicular Scan) Technetium-99m pertechnetate scintigraphy can differentiate torsion (photopenic area) from inflammation (increased uptake). Largely replaced by Doppler US in Australian centres but may be useful when US is equivocal and expertise is available. Limited availability (tertiary centres).
Specialist MRI Scrotum High sensitivity for testicular rupture and intratesticular masses. Reserved for equivocal US findings or when US is non-diagnostic. Limited availability; not suitable for time-critical presentations.
ℹ️
Imaging should never delay surgical consultation when clinical suspicion of testicular torsion is high. In many Australian emergency departments, the surgeon is contacted before imaging is arranged. If the on-call surgical team cannot review the patient within 30 minutes and US cannot be performed urgently, surgical exploration based on clinical assessment alone is appropriate.

Empirical & Directed Therapy

Analgesic Management

💊
Ibuprofen
Nurofen® · Brufen® · NSAID
Adult dose 400–600 mg PO TDS (max 2.4 g/day); take with food
Paediatric dose 5–10 mg/kg PO TDS (max 30 mg/kg/day)
Renal adjustment Avoid if eGFR <30 mL/min
PBS status ✔ PBS General Benefit
💊
Paracetamol
Panadol® · Panamax® · Analgesic
Adult dose 1 g PO QID PRN (max 4 g/day)
Paediatric dose 15 mg/kg PO QID PRN (max 60 mg/kg/day)
Hepatic adjustment Max 2 g/day in hepatic impairment or chronic alcohol use
PBS status ✔ PBS General Benefit
💊
Oxycodone
Endone® · OxyNorm® · Opioid
Adult dose 5–10 mg PO/IM every 4–6 hours PRN for severe pain
Renal adjustment Reduce dose by 50% if eGFR 10–50 mL/min; avoid if eGFR <10 mL/min
PBS status ✔ PBS General Benefit

Antiemetic

💊
Ondansetron
Zofran® · 5-HT3 antagonist
Adult dose 4 mg IV/ODT (orally disintegrating tablet) stat, may repeat ×1
Paediatric dose 0.15 mg/kg IV (max 4 mg)
PBS status ✔ PBS General Benefit

Quick Reference: Therapy by Diagnosis

Testicular torsion
Surgical exploration + bilateral orchidopexy
Emergency
IV morphine 0.1 mg/kg + ondansetron 4 mg pre-op. Manual detorsion as temporising measure.
STI-related epididymo-orchitis
Ceftriaxone 500 mg IM stat + doxycycline 100 mg PO BD
10–14 days (doxycycline)
NSAIDs for pain. Scrotal elevation. Partner notification. STI screen including HIV/syphilis.
UTI-related epididymo-orchitis
Trimethoprim 300 mg PO daily OR ciprofloxacin 500 mg PO BD
14 days
Treat underlying cause (e.g., BPH, catheter-related). Consider urology referral if recurrent.
Appendage torsion
Ibuprofen 5–10 mg/kg PO TDS (paeds) / 400 mg PO TDS (adults)
5–7 days
Self-limiting. Scrotal support. Ice packs. Review if worsening.
Testicular trauma (contusion)
Paracetamol + ibuprofen; scrotal support; ice packs
1–2 weeks
Repeat US in 1–2 weeks if haematocele present. Surgical exploration if rupture suspected.
Testicular malignancy
Radical inguinal orchidectomy → staging → adjuvant therapy per MDT
Urgent urology referral (within 1–2 weeks)
Tumour markers before surgery. CT staging. Refer to specialised testicular cancer MDT.

Monitoring & Follow-Up

Post-Operative Monitoring (Torsion)

  • Wound review at 1–2 weeks post-operatively
  • Follow-up scrotal US at 3–6 months to assess testicular viability and volume
  • Semen analysis at 3–6 months if fertility is a concern (especially if orchidectomy was required)
  • Assessment of testosterone levels if bilateral pathology or orchidectomy was performed
  • Counselling regarding fertility implications — some degree of subfertility may occur even after successful orchidopexy due to anti-sperm antibody development

Monitoring for Epididymo-Orchitis

  • Clinical review at 7–14 days to confirm symptom resolution and antibiotic completion
  • If symptoms fail to improve within 48–72 hours of appropriate antibiotics: reassess diagnosis (consider torsion, abscess, testicular tumour), repeat US, and consider urology referral
  • Test of cure NAAT for chlamydia/gonorrhoeae at 4 weeks if STI-related (recommended by some guidelines, though not universally required)
  • Repeat STI screen at 3 months (reinfection risk) — Australian STI guidelines recommend
  • Assess for complications: testicular abscess (may require surgical drainage), chronic epididymitis, testicular atrophy

Testicular Tumour Monitoring

  • Post-orchidectomy tumour markers (AFP, β-hCG, LDH) at intervals determined by staging and histology
  • Surveillance protocols per Cancer Council Australia / Australian and New Zealand Urogenital and Prostate Cancer Trials Group guidelines
  • Regular CT surveillance for stage I NSGCT: typically CT at 3, 6, 12, 18, and 24 months
  • Psychosocial support: testicular cancer diagnosis in young men may impact body image, sexual function, and fertility — early referral to supportive care services

Special Populations

👶

Paediatrics

Neonatal torsion: Extravaginal torsion (the tunica vaginalis has not yet fused to the dartos fascia). Usually presents as a hard, painless scrotal mass at birth. Often non-salvageable by the time of diagnosis. Urgent surgical exploration is still recommended (within 6–12 hours if possible). Contralateral orchidopexy should be performed.
Pre-pubertal boys: Acute scrotal pain most commonly due to torsion of the testicular appendage (7–14 years) or testicular torsion. Aetiology of epididymo-orchitis in this age group is typically UTI-related (not STI); investigate for underlying urological anomalies (posterior urethral valves, vesicoureteric reflux).
Adolescents: Peak age for testicular torsion (12–18 years). Pain and embarrassment may delay presentation. Brief, non-judgemental history-taking without a parent present may be appropriate to discuss sexual history and exclude STI-related epididymo-orchitis. Gillick competence applies.
Paracetamol: 15 mg/kg PO QID PRN (max 60 mg/kg/day or 4 g/day). Ibuprofen: 5–10 mg/kg PO TDS. Ondansetron: 0.15 mg/kg IV/PO (max 4 mg).
🤰

Pregnancy Considerations

While scrotal pain in pregnancy is not applicable (male condition), the pregnant partner of a male with STI-related epididymo-orchitis must be screened and treated concurrently. Chlamydia and gonorrhoeae in pregnancy are associated with preterm labour, premature rupture of membranes, and neonatal ophthalmia.
Contact sexual health services for coordinated partner management.
👴

Elderly

Males >60 years: Acute scrotal pain most commonly due to UTI-related epididymo-orchitis (associated with bladder outlet obstruction from BPH, catheter-related UTI, or urological instrumentation). Torsion is rare in this age group but must still be considered.
Fournier's gangrene: Necrotising fasciitis of the perineum and genitalia — predominantly affects middle-aged and elderly men with diabetes mellitus, immunosuppression, or chronic alcohol use. Presents with rapidly progressive pain, swelling, crepitus, and systemic sepsis. Requires emergency surgical debridement and broad-spectrum IV antibiotics (piperacillin-tazobactam + clindamycin).
Renal dose adjustment: Trimethoprim — caution in renal impairment; fluoroquinolones — dose reduction required if eGFR <30 mL/min.
🫘

Renal Impairment

Ceftriaxone: No dose adjustment required in renal impairment — preferred cephalosporin for STI cover in CKD.
Doxycycline: No dose adjustment required; however, use with caution in severe renal impairment (risk of hepatotoxicity). Monitor LFTs.
Trimethoprim: Avoid or reduce dose if eGFR <30 mL/min — risk of hyperkalaemia and worsening renal function. Consult infectious diseases.
Ciprofloxacin: Reduce to 250–500 mg PO daily if eGFR <30 mL/min.
NSAIDs: Avoid ibuprofen and naproxen if eGFR <30 mL/min. Use paracetamol ± oxycodone (reduced dose) for analgesia.
🫁

Hepatic Impairment

Paracetamol: Maximum 2 g/day in hepatic impairment or chronic alcohol use.
Doxycycline: Use with caution; monitor LFTs in chronic liver disease.
Metronidazole: Avoid in severe hepatic impairment (if being used for Fournier's gangrene cover).
Adjust analgesic approach: avoid or reduce opioid doses; consider paracetamol monotherapy with dose capping.
🛡️

Immunocompromised

HIV-positive males: Increased risk of testicular lymphoma and seminoma. Also at higher risk of opportunistic orchitis (TB, CMV, fungal). Broaden differential diagnosis. Discuss with infectious diseases team if atypical presentation.
Transplant recipients / patients on immunosuppression: Atypical infections may present with scrotal pain. Lower threshold for US and biopsy if suspicious intratesticular lesion.
Diabetes mellitus: Independent risk factor for Fournier's gangrene and complicated epididymo-orchitis. Glycaemic optimisation is important alongside antimicrobial therapy.
Aboriginal and Torres Strait Islander Health
Epidemiology
Aboriginal and Torres Strait Islander males have higher rates of sexually transmissible infections (chlamydia, gonorrhoea) compared with non-Indigenous Australians, particularly in remote and very remote communities. Gonorrhoea notification rates are up to 10 times higher in Indigenous Australians. This increases the burden of STI-related epididymo-orchitis in these populations. Rates of testicular cancer are lower in Indigenous compared to non-Indigenous Australian males.
Access to care
Significant barriers exist to timely presentation and specialist access in rural and remote communities. The average distance to a hospital with urology services may exceed 500 km in remote NT, WA, and QLD communities. Retrieval times for suspected testicular torsion may exceed the 6-hour salvage window. Point-of-care testing and telemedicine can support initial assessment, but surgical capability requires transfer to a regional or tertiary centre.
Cultural considerations
Scrotal and genital symptoms may carry cultural stigma and embarrassment, particularly in communities where sexual health discussions are culturally sensitive. Gender-concordant healthcare providers are preferred where possible. Avoid assumptions about sexual behaviour; use non-judgemental, yarning-based communication. Acknowledge that some men may present late due to cultural factors, stoicism, or previous negative healthcare experiences.
STI management
Implement the Australian STI Management Guidelines for use in Aboriginal and Torres Strait Islander populations (ASHM/RACGP). Azithromycin 1 g PO stat is an alternative to doxycycline for chlamydial epididymo-orchitis where adherence to a 10–14 day course is a concern (noting increasing azithromycin resistance in some M. genitalium isolates). Ensure partner notification through community-controlled health services where available.
Remote management
Health practitioners in remote communities should be trained in basic scrotal examination and the clinical diagnosis of suspected torsion. Clinical guidelines such as CARPA Standard Treatment Manual (7th edition) provide remote-area management algorithms. Where torsion is suspected and transfer is delayed, consider discussion with surgical team regarding telephone-guided manual detorsion. Ensure emergency antibiotic kits for epididymo-orchitis are available in remote health clinics (ceftriaxone for IM administration).
Health promotion
Targeted health promotion regarding testicular self-examination and recognition of scrotal symptoms should be delivered through community-controlled health organisations such as the National Aboriginal Community Controlled Health Organisation (NACCHO) and state/territory affiliates. Young Aboriginal and Torres Strait Islander men should be empowered to present early with testicular symptoms — messaging should be culturally appropriate, use local language where possible, and involve male community leaders.

📚 References

  1. 1. Sharp VJ, Kieran K, Arlen AM. Testicular torsion: diagnosis, evaluation, and management. Am Fam Physician. 2013;88(12):835–840.
  2. 2. Trojian TH, Lishnak TS, Heiman D. Epididymitis and orchitis: an overview. Am Fam Physician. 2009;79(7):583–587.
  3. 3. Australian Government Department of Health and Aged Care. Third National Sexually Transmissible Infections Strategy 2018–2022. Canberra: Commonwealth of Australia; 2019.
  4. 4. Ringdahl E, Teague L. Testicular torsion. Am Fam Physician. 2006;74(10):1739–1743.
  5. 5. RACGP. Australian STI Management Guidelines for Use in Primary Care. Melbourne: RACGP; 2023. Available at: https://www.sti.guidelines.org.au.
  6. 6. Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2023. AIHW; Canberra 2023.
  7. 7. Cancer Council Australia Testicular Cancer Guidelines Working Party. Clinical Practice Guidelines for the Management of Testicular Cancer. Sydney: Cancer Council Australia; 2023.
  8. 8. Bhatt S, Dogra VS. Role of US in testicular and scrotal trauma. Radiographics. 2008;28(6):1617–1629.
  9. 9. Gatti JM, Murphy JP. Current management of the acute scrotum. Semin Pediatr Surg. 2007;16(1):58–63.
  10. 10. Kimber C, Spitz L, Drake D. Testicular torsion in neonates — the need for vigilance. Br J Urol. 2000;85(7):925–927.
  11. 11. National Aboriginal Community Controlled Health Organisation (NACCHO). Sexual Health: Aboriginal and Torres Strait Islander People. Canberra: NACCHO; 2022.
  12. 12. Central Australian Rural Practitioners Association (CARPA). Standard Treatment Manual. 7th ed. Alice Springs: CARPA; 2023.
  13. 13. Walker D, Ha T, Tran D. Fournier gangrene: a review of the presentation, diagnosis, and management. Aust J Gen Pract. 2020;49(9):585–590.
  14. 14. Ku JH, Kim ME, Lee NK, Park YH. Management of testicular trauma: the efficacy of colour Doppler ultrasound in predicting the need for surgical exploration. BJU Int. 2001;87(8):733–738.
for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.
Preventive health
Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction
Paracetamol ± NSAID; manual therapy
2–6 weeks
Provocable on palpation; no red flags
Thoracic compression fracture
Paracetamol; ± calcitonin; DXA + osteoporosis Rx
6–12 weeks healing
Elderly; osteoporosis; acute onset
ACS (posterior MI)
Aspirin 300 mg, GTN, heparin; urgent PCI
Time-critical
ECG, troponin; CV risk factors
Aortic dissection
IV labetalol; urgent CT aortogram; surgery (Type A)
Time-critical
Tearing pain; BP differential >20 mmHg
Vertebral osteomyelitis
IV antibiotics (vancomycin + ceftriaxone initially); ID consult
6 weeks IV antibiotics
Fever, elevated CRP, IV drug use
Biliary colic / cholecystitis
Paracetamol ± morphine; lap cholecystectomy
Surgical within 72 h (cholecystitis)
RUQ/infrascapular; post-prandial; RUQ US

📚 References

  1. 1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
  2. 2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
  3. 3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
  4. 4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
  5. 5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
  6. 6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
  7. 7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  8. 8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
  9. 9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
  10. 10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
  11. 11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
  12. 12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).